Document is current

Article History

Received: 3 August 2025

Accepted: 7 October 2025

First Online: 16 October 2025

Declarations

:

: Francisco Javier Melgosa Ramos has received honoraria and/or travel grants and/or has acted as an advisory board member for Novartis, Abbvie, Janssen Cilag, UCB, Lilly, LEO Pharma, L’Oreal, Sanofi, Almirall, and Amgen. Antonio Martorell has received honoraria and/or travel grants and/or has acted as an advisory board member or principal investigator in clinical trials for Incyte, Moonlake, MSD, Novartis, Abbvie, Johnson & Johnson, UCB, Lilly, LEO Pharma, Takeda, Sanofi, Almirall, and Amgen. Esperanza Martínez Ruiz, Marta Galarreta Pascual, and Virginia Sanz-Motilva have no conflicts of interest to declare.

: This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments, and also in compliance with national regulations and ethical principles governing biomedical research in Spain. According to national legislation (Law 14/2007 on Biomedical Research and the EU General Data Protection Regulation [GDPR] 2016/679), research involving anonymized data may be exempt from requiring institutional review board (IRB) approval. In this case, as a result of the full anonymization of the data and because this manuscript describes a retrospective case series of three patients, formal approval from a research ethics committee was not required, in accordance with current Spanish legislation and institutional policies. The patients in this manuscript have given informed consent to the publication of their case details and photographs.